SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-156965
Filing Date
2021-05-11
Accepted
2021-05-11 07:15:29
Documents
3
Period of Report
2021-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d484034d8k.htm 8-K 18889
2 EX-99.1 d484034dex991.htm EX-99.1 77274
3 GRAPHIC g484034dsp4.jpg GRAPHIC 6275
  Complete submission text file 0001193125-21-156965.txt   106112
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 21909596
SIC: 2836 Biological Products, (No Diagnostic Substances)